PHAXIAM Therapeutics S.A. – NASDAQ:PHXM

Market closed

Open in about 8 hours

-21.88%

month

-19.01%

quarter

Market Cap	19.85M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	N/A

Revenue	N/A
EBITDA	N/A
Income	N/A
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

PHAXIAM Therapeutics S.A. (NASDAQ:PHXM): Profit margin
Sep 2022	0	-5.13M
Dec 2022	0	5.93M
Jun 2023	0	0
Sep 2023	0	-5.69M

PHAXIAM Therapeutics S.A. Financials Estimate

Q Y

PHAXIAM Therapeutics S.A. (NASDAQ:PHXM): Analyst Estimates
2025	0	-18.91M
2026	0	-19.37M

Analysts Price target
Financials & Ratios estimates

PHAXIAM Therapeutics S.A. (NASDAQ:PHXM): Debt to assets
Dec 2021	66768000	43.92M	65.78%
Jun 2022	65987000	43.55M	66%
Dec 2022	45811000	22.32M	48.73%
Jun 2023	65531000	28.89M	44.1%

PHAXIAM Therapeutics S.A. (NASDAQ:PHXM): Cash Flow
Sep 2019	-12.85M	-1.75M	-461K
Dec 2019	-6.63M	-515K	-341K
Dec 2022	-11.1M	180K	-3.72M
Jun 2023	0	0	0

PHAXIAM Therapeutics S.A. alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

PHAXIAM Therapeutics S.A.
Employees

PHAXIAM Therapeutics S.A. (NASDAQ:PHXM): Employee count
Sep 2023	49
Oct 2023	45
Nov 2023	45
Dec 2023	49
Jan 2024	49
Feb 2024	49
Mar 2024	49
Apr 2024	49
May 2024	49
Jun 2024	49
Jul 2024	49

PHAXIAM Therapeutics S.A.
Earnings Call Transcripts

Quarter	Transcript
Q3 2023 17 Nov 2023	Q3 2023 Earnings Call Transcript
Q1 2023 13 May 2023	Q1 2023 Earnings Call Transcript
Q3 2022 22 Nov 2022	Q3 2022 Earnings Call Transcript
Q2 2022 13 Sep 2022	Q2 2022 Earnings Call Transcript

PHXM earnings call transcripts

PHAXIAM Therapeutics S.A.
Latest News

Wednesday, 27 November 2024
08:30	PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area	globenewswire.com
Monday, 18 November 2024
12:00	PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"	globenewswire.com
Wednesday, 13 November 2024
11:45	PHAXIAM Reports Third-Quarter 2024 Financial Information	globenewswire.com
Monday, 4 November 2024
12:00	PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.	globenewswire.com
Wednesday, 25 September 2024
11:45	PHAXIAM Provides Business and Financial Update For the First Half of 2024	globenewswire.com
Friday, 28 June 2024
11:45	Results of the Combined General Meeting of 28 June 2024	globenewswire.com
Wednesday, 15 May 2024
11:45	PHAXIAM provides Business and Financial Update for the First Quarter of 2024	globenewswire.com
Monday, 15 April 2024
01:30	PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus	globenewswire.com
Friday, 5 April 2024
12:00	PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)	globenewswire.com
Thursday, 21 March 2024
13:02	PHAXIAM Therapeutics S.A. (ERYFF) Q4 2023 Earnings Call Transcript	seekingalpha.com
Wednesday, 20 March 2024
13:00	PHAXIAM Announces 2023 Full-Year Results and Provides Business Update	globenewswire.com
Monday, 11 March 2024
02:00	PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market	globenewswire.com
Tuesday, 20 February 2024
16:05	PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market	globenewswire.com
Thursday, 18 January 2024
16:05	PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024	globenewswire.com
Friday, 17 November 2023
18:29	PHAXIAM Therapeutics S.A. (PHXM) Q3 2023 Earnings Call Transcript	Seeking Alpha

Frequently Asked Questions (FAQ)

When is PHAXIAM Therapeutics S.A.'s next earnings date?

Unfortunately, PHAXIAM Therapeutics S.A.'s (PHXM) next earnings date is currently unknown.
Does PHAXIAM Therapeutics S.A. pay dividends?

No, PHAXIAM Therapeutics S.A. does not pay dividends.
How much money does PHAXIAM Therapeutics S.A. make?

PHAXIAM Therapeutics S.A. has a market capitalization of 19.85M.
What is PHAXIAM Therapeutics S.A.'s stock symbol?

PHAXIAM Therapeutics S.A. is traded on the NASDAQ under the ticker symbol "PHXM".
What is PHAXIAM Therapeutics S.A.'s primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of PHAXIAM Therapeutics S.A.?

Shares of PHAXIAM Therapeutics S.A. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does PHAXIAM Therapeutics S.A. have?

As Jul 2024, PHAXIAM Therapeutics S.A. employs 49 workers.
When PHAXIAM Therapeutics S.A. went public?

PHAXIAM Therapeutics S.A. is publicly traded company for more then 7 years since IPO on 26 Oct 2017.
What is PHAXIAM Therapeutics S.A.'s official website?

The official website for PHAXIAM Therapeutics S.A. is erytech.com.
How can i contact PHAXIAM Therapeutics S.A.?

PHAXIAM Therapeutics S.A. can be reached via phone at +33 4 78 74 44 38.

PHAXIAM Therapeutics S.A.

erytech.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

+33 4 78 74 44 38

60 Avenue Rockefeller
Lyon, 69008

CIK: 0001624422
ISIN: US29604W2070
: